Results 231 to 240 of about 67,560 (281)

SORBS2: A Molecular Nexus in Multisystem Diseases Through Scaffold‐Mediated Regulation

Journal of Cellular and Molecular Medicine, Volume 30, Issue 9, May 2026.
ABSTRACT Sorbin and SH3 Domain Containing 2 (SORBS2), a multifunctional scaffold protein harbouring Sorbin homology (SoHo) and Src homology 3 (SH3) domains, serves as a molecular hub in human diseases by integrating cytoskeletal remodelling, signal transduction and RNA metabolic regulation. This study systematically analyses SORBS2's molecular features,
Qiwei Jia, Yong Zhang
wiley   +1 more source

Untargeted Metabolomic and Lipidomic Profiles of Gingival Crevicular Fluid in the Context of Periodontitis

Journal of Clinical Periodontology, Volume 53, Issue 5, Page 774-783, May 2026.
ABSTRACT Aim(s) This cross‐sectional clinical study aimed to explore the untargeted metabolomic and lipidomic profiles in gingival crevicular fluid (GCF) obtained from healthy individuals and patients with periodontitis. Materials and Methods GCF was collected from 17 periodontally healthy and 19 periodontitis patients.
Caroline H. Henderzahs, Chiaki Yamada, Alexandr Morozov, Thelmalane Yalartai, Vanchit John, Hawra AlQallaf, Alexandru Movila   +6 more
wiley   +1 more source

Hyaluronic Acid Dermal Filler‐Associated Vascular Occlusion—A Review of Prevention and Management Strategies

Journal of Cosmetic Dermatology, Volume 25, Issue 5, May 2026.
ABSTRACT Background Significant complications are uncommon with aesthetic hyaluronic acid (HA) dermal fillers, but inadvertent injection of dermal filler into an artery can result in tissue damage, scarring, visual loss, and even stroke. Practitioners must therefore reduce this risk through proactive, preventative techniques.
Stephen Lowe
wiley   +1 more source

PHR1 mediates rapid high light responses and acclimation to high photosynthetic activity

The Plant Journal, Volume 126, Issue 3, May 2026.
SUMMARY Changing light intensity requires immediate metabolic adjustment which involves reprogramming of both plastidial and nuclear gene expression, but the signaling pathways behind such responses are not fully understood. Here we report that an increase in light intensity causes fluctuations of Pi levels in the chloroplasts of Arabidopsis thaliana ...
Lukas Ackermann, Agnes Fekete, Laura Schröder, Thomas Nägele, Alina J. Hieber, Monika Müller, Martin J. Mueller, Maria Klecker   +7 more
wiley   +1 more source

Dysregulation of CD39/Ectonucleoside Triphosphate Diphosphohydrolase 1 Causes Urinary Bladder Dysfunction with Abnormal Smooth Muscle Contractility

The FASEB Journal, Volume 40, Issue 7, 15 April 2026.
Abnormal extracellular ATP levels cause lower urinary tract symptoms (LUTS). Here, we demonstrate that overexpression of ENTPD1 (CD39TG)—an ATP/ADP converting enzyme—reduces voiding frequency while increasing void volume. Conversely, ENTPD1 deficiency results in frequent, small‐volume voiding.
Zhaobo Luo, Huan Chen, Ali Wu, Weipu Mao, Sagar Barge, Seth L. Alper, Simon C. Robson, Weiqun Yu   +7 more
wiley   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Phosphodiesterase Type 5 Inhibitors for Pulmonary Arterial Hypertension

New England Journal of Medicine, 2009
A 46-year-old-woman presents with exertional dyspnea and syncope and receives a diagnosis of idiopathic pulmonary arterial hypertension. Treatment with sildenafil is recommended. Sildenafil and tadalafil are phosphodiesterase type 5 inhibitors that ameliorate pulmonary arterial hypertension by increasing levels of cyclic guanosine monophosphate in the ...
Stephen L, Archer, Evangelos D, Michelakis   +1 more
exaly   +6 more sources

Phosphodiesterase type 5 inhibitors for erectile dysfunction

BJU International, 2005
This is our first presentation of Great Drug Classes, and we start with a description of phosphodiesterase type 5 inhibitors and their use in erectile dysfunction. This is an in‐depth review of this class of drugs, offering the reader a description of how they work, in which conditions they may be particularly beneficial, and a ...
Culley C, Carson, Tom F, Lue
openaire   +4 more sources

Phosphodiesterase Type 5 Inhibitors: Unmet Needs

Current Pharmaceutical Design, 2009
Erectile dysfunction (ED) has been revolutionized during the last two decades, as several treatment options are available today. Phosphodiesterase type 5 (PDE5) inhibitors (sildenafil, tadalafil, vardenafil) are currently the first choice treatment option for ED by most physicians and patients due to their high efficacy rates and favourable safety ...
K, Hatzimouratidis, D G, Hatzichristou
openaire   +2 more sources

Phosphodiesterase Type 5 Inhibitors: The Day After

European Urology, 2007
Review the literature on phosphodiesterase type 5 inhibitors (PDE5-Is), addressing critical issues in their current and future use, assessing unanswered questions, and identifying research needs.A MEDLINE search was conducted on PDE5-Is, with emphasis on clinical trials and experience, for interpretation and analysis of their present and future role ...
Konstantinos, Hatzimouratidis, Dimitrios, Hatzichristou   +1 more
openaire   +2 more sources

Phosphodiesterase Type 5 (PDE5) Inhibitors

2003
Publisher Summary In recent years, the field of Phosphodiesterase Type 5 (PDE5) inhibitors has reached a state of maturity. Standard issues in medicinal chemistry, such as potency, selectivity, physico-chemical properties and oral bioavailability, have been successfully addressed with the known PDE5 inhibitors.
Helmut, Haning, Ulrich, Niewöhner, Erwin, Bischoff   +2 more
openaire   +2 more sources